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Insulin resistance is characteristic of pregnancies where the mother shows metabolic alterations, such as preeclampsia (PE) and
gestational diabetes mellitus (GDM), or abnormal maternal conditions such as pregestational maternal obesity (PGMO). Insulin
signalling includes activation of insulin receptor substrates 1 and 2 (IRS1/2) as well as Src homology 2 domain-containing
transforming protein 1, leading to activation of 44 and 42 kDa mitogen-activated protein kinases and protein kinase B/Akt (Akt)
signalling cascades in the human foetoplacental vasculature. PE, GDM, and PGMO are abnormal conditions coursing with
reduced insulin signalling, but the possibility of the involvement of similar cell signalling mechanisms is not addressed. This
review aimed to determine whether reduced insulin signalling in PE, GDM, and PGMO shares a common mechanism in the
human foetoplacental vasculature. Insulin resistance in these pathological conditions results from reduced Akt activation mainly
due to inhibition of IRS1/2, likely due to the increased activity of the mammalian target of rapamycin (mTOR) resulting from
lower activity of adenosine monophosphate kinase. Thus, a defective signalling via Akt/mTOR in response to insulin is a central
and common mechanism of insulin resistance in these diseases of pregnancy. In this review, we summarise the cell signalling
mechanisms behind the insulin resistance state in PE, GDM, and PGMO focused in the Akt/mTOR signalling pathway in the
human foetoplacental endothelium.
1. Introduction
Insulin modulates D-glucose homeostasis, and a reduced
response or a lack of response to this hormone (hereafter
referred as “insulin resistance”) is characteristic in several
pathologies, including diabetes mellitus and obesity [1, 2].
Insulin resistance tightly relates with abnormal responses of
the vascular endothelium, that is, endothelial dysfunction,
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to vasoactive molecules including insulin and the endoge-
nous nucleoside adenosine [3, 4]. Human pregnancy courses
with physiological maternal and foetal insulin resistance as
an adaptive response to the increasing nutrient requirement
by the pregnant women and the growing foetuses [5].
Insulin signalling involves preferential activation of the
protein kinase B (PKB)/Akt (Akt) and mitogen-activated
protein kinase (MAPK) signalling pathways [4, 6]. Vascular
actions of insulin in the human placenta and umbilical cord
vessels (hereafter referred as “foetoplacental vasculature”)
are of relevance since this vascular bed lacks innervation,
and the control of the blood ﬂux results from local release
of vasoactive molecules [4, 7]. The mechanisms behind vas-
cular insulin eﬀects include the synthesis of nitric oxide
(NO) by the endothelial NO synthase (eNOS) isoform,
ATP release, and adenosine-mediated increase of L-
arginine transport and NO synthesis [4, 8, 9]. Pathologies
of pregnancy, such as preeclampsia (PE) [10] and gestational
diabetes mellitus (GDM) [4, 11], and abnormal maternal
conditions, such as pregestational maternal obesity (PGMO)
and maternal obesity in pregnancy [12], show with reduced
insulin signalling in the foetoplacental vasculature. In this
review, we propose that common signalling mechanisms
result in insulin resistance of the human foetoplacental vas-
culature in these diseases.
2. Insulin Signalling
Insulin activates the splice variants A (IR-A) and B (IR-B) of
insulin receptors (IRs) in the human foetoplacental vascula-
ture [13]. IR-A and IR-B are expressed in this vascular bed
with IR-A showing higher aﬃnity for insulin than that with
IR-B [4, 13, 14]. IR activation by β-subunit autophosphoryla-
tion recruits and phosphorylates two protein families, that is,
the insulin receptor substrates (IRSs) and the Src homology 2
domain-containing transforming protein 1 (SHc) [15]
(Figure 1). IRSs have at least six members (IRS-1 to IRS-6),
where IRS-1 and IRS-2 are the most characterized [15].
SHc corresponds to at least three diﬀerent proteins (SHcA,
SHcB, and SHcC), with SHcA being expressed in mammals
as the alternative splicing isoforms SHcA 46, SHcA 52, and
SHcA 66 [16]. IRS-1 and IRS-2 are major activators of Akt
via phosphatidylinositol 3 kinase (PI3K) compared with a
minor eﬀect on 44 and 42 kDa mitogen-activated protein
kinases (p44/42mapk); instead, SHcA preferentially activates
p44/42mapk via the growth factor receptor-bound protein 2
(Grb2) [17]. However, whether stimulation of IR-A or IR-B
results in diﬀerential SHc or IRS activation and signalling is
unknown. The physiological response of most tissues in the
human body, including the foetoplacental vasculature, is that
activation of p42/44mapk and Akt signalling pathways results
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Figure 1: Insulin signalling in the human feotoplacental vasculature. Insulin activates insulin receptors A (IR-A) and B (IR-B) leading to
recruitment and activation of insulin receptor substrates 1 and 2 (IRS1/2) and Src homology 2 domain-containing transforming protein
1 type A of 42 and 56 kDa (SHcA42/56). IR-A activation causes preferential activation of SHcA42/56, which triggers signalling through
the growth factor receptor-bound protein 2 (Grb2) cascade ending in higher (⇧) activity of the 44 and 42 kDa mitogen-protein kinases
(p44/42mapk). IR-B activation causes preferential activation of IRS1/2, which triggers signalling through the phosphatidylinositol 3 kinase
(PI3K) cascade ending in higher protein kinase B/Akt (Akt) activity. IR-A signalling and IR-B signalling increase the endothelial nitric
oxide (NO) synthase (eNOS) activity to generate nitric oxide (NO). An increase in the NO synthesis results in relaxation of the
foetoplacental vascular beds (vasodilation).
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in increased eNOS expression and activity leading to vasodila-
tion [4, 18]. However, under pathological conditions, the equi-
librium between signalling associated with IR-A and IR-B
activation by insulin is lost and a preferential activation of
p42/44mapk or Akt is reported. Several studies describe a vari-
ety of cell signalling mechanisms potentially involved in these
alterations of insulin response; however, upstream- and
downstream-associated signalling pathways are not addressed.
3. Insulin Resistance
Insulin resistance is seen in subjects where the metabolic
handling of D-glucose is deﬁcient [2]. PE [19, 20], GDM
[21, 22], and obesity in pregnancy [23] show with insulin
resistance in the mother, foetus, and newborn. However,
whether insulin resistance results from or is the cause of these
pathological conditions is still unclear.
Several studies show that IRS-1-mediated activation of
PI3K leads to formation of phosphatidylinositol triphos-
phate, the substrate for the human 3-phosphoinositide-
dependent protein kinase 1 (PDK1), which activates Akt
[15] (Figure 2). However, in insulin resistance, IR-B prefer-
ential activation by insulin results in IRS1/2-mediated
increase in the activity of the p85α regulatory subunit of
PI3K (PI3K p85α), which inhibits Akt thus reducing NO
generation. Other reports show that Akt activation mediates
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Figure 2: Cell signalling in insulin resistance in the human foetoplacental vasculature. Insulin activates insulin receptors A (IR-A) and B
(IR-B) leading to recruitment and activation of insulin receptor substrates 1 and 2 (IRS1/2) and Src homology 2 domain-containing
transforming protein 1 type A of 42 and 56 kDa (SHcA42/56). IR-A activation causes preferential activation of SHcA42/56, which
triggers signalling through the growth factor receptor-bound protein 2 (Grb2) ending in increased (⇧) activity of the 44 and 42 kDa
mitogen-protein kinases (p44/42mapk) and c-Jun N-terminal kinases (JNK). IR-B activation causes preferential activation of IRS1/2
triggering signalling by the p85α regulatory subunit of phosphatidylinositol 3 kinase (PI3K p85α). Activation of this subunit of PI3K
decreases (⇩) the protein kinase B/Akt (Akt) activity ending in reduced endothelial nitric oxide (NO) synthase (eNOS) activity and NO
generation. Reduced Akt activity also results in lower activity of the mammalian target of rapamycin (mTOR) activity, which turns into
reduced activity of the adenosine monophosphate protein kinase (AMPK). Reduced AMPK activity is also caused by the reduced plasma
level of adiponectin (an AMPK-activator) thus releasing AMPK-inhibition of mTOR facilitating activation of this molecule. This
phenomenon potentially (?) increases mTOR-activated signalling through p70 S6 kinase 1 (S6K1) thus reducing IRS1/2 signalling. The
increased extracellular level of leptin and tumour necrosis factor α (TNFα) results in JNK activation. The possibility that JNK increases
the inhibitor phosphorylation of IRS1/2 (Ser312) reducing insulin signalling (?) is likely. All in concert, these mechanisms lead to a
state of lower response to insulin of the human foetoplacental vasculature (insulin resistance). Blue arrows denote activation. Red
arrows denote inhibition.
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increased activity of the mammalian target of rapamycin
(mTOR), a regulator of cell proliferation, adhesion, migra-
tion, invasion, metabolism, and survival [24]. Interestingly,
mTOR signals through p70 S6 kinase 1 (S6K1) which reduces
insulin signalling by inhibiting IRSs-activity-mediated acti-
vation of Akt [25, 26]. Thus, a modulatory loop to keep a
physiological Akt activity and therefore insulin signalling to
cause vasodilation involves mTOR activation/deactivation
depending on the state of activation of Akt. When mTOR is
upregulated, the physiological consequences are reduced
Akt-mediated, NO-dependent vascular responses to insulin.
Other reports address that mTOR activity is inhibited by
the adenosine monophosphate kinase (AMPK) [27], a mole-
cule considered as general sensor of the cell energy state get-
ting activated in response to a lower ATP/AMP ratio [28, 29].
AMPK activation results in increased eNOS activator phos-
phorylation at serine 1177 (Ser1177) and serine 615 (Ser615)
in the vasculature [30]. Interestingly, AMPK activation
increased the activity of PI3K/Akt/eNOS signalling cascade
leading to higher NO generation and prevented the high D-
glucose-impaired response to insulin in human umbilical
vein endothelial cells (HUVECs) [31]. Thus, it is suggested
that AMPK will increase insulin signalling due to its capacity
to inhibit mTOR in the human foetoplacental vasculature.
Activation of p44/42mapk triggers c-Jun N-terminal
kinase (JNK) signalling in HUVECs, resulting in IRS inhibi-
tion [32, 33] (Figure 2). Since S6K1 activation by mTOR
results in p44/42mapk- and Akt-reduced activity in HUVECs
[34] and insulin-dependent activation of p44/42mapk inhibits
AMPK in the rat skeletal muscle cell line L6 [35], a functional
dependency between p44/42mapk, AMPK, andmTOR activity
may also be a phenomenon involved in impaired insulin
sensitivity in the foetoplacental vasculature.
It is well described that proinﬂammatory cytokine
tumour necrosis factor α (TNFα) [36] and the adipocytokine
adiponectin [37] and leptin [38] play crucial roles in insulin
resistance. TNFα activates the JNK signalling pathway in
HUVECs [39] resulting in inhibition of IRS-1 and reduced
Akt-mediated insulin signalling [40–42] (Figure 2). Interest-
ingly, higher plasma TNFα is found late in pregnancy (34–36
weeks of gestation) suggesting a likely reduced insulin biolog-
ical action at this stage of pregnancy [43]. Adiponectin keeps
insulin signalling (i.e., acts as insulin sensitizer) increasing
the IRS-dependent signalling pathway by activating AMPK
[37] and, subsequently, inhibiting mTOR [44]. Interestingly,
a reduced plasma level of adiponectin is reported in pregnant
women with diabetes mellitus [36]. Since the maternal
plasma TNFα level is elevated in PE [45], GDM [46], or obese
pregnant women [47], a potential TNFα-dependent inhibi-
tion of adiponectin release in insulin resistance in pregnant
women, and perhaps the foetus, is likely. However, whether
TNFα regulates adiponectin release in pregnancy is still
unknown. Leptin is released in obesity in response to accu-
mulating subcutaneous fat and increased fatty acid oxidation
[38], a phenomenon regarded as a state of higher insulin
resistance [38, 48]. Additionally, leptin activates JNK leading
to inhibition of IRS1/2 and reduced insulin sensitivity
[32, 33]. Since (i) leptin also increases the generation of
reactive oxygen species (ROS) in HUVECs [49], (ii)
superoxide anion (O2
−), the most reactive ROS, scavenges
NO [30], and (iii) ROS activates JNK in this cell type [49],
a leptin/ROS (probably O2
−)/JNK pathway is likely described
as a mechanism leading to reduced insulin sensitivity in the
human foetoplacental vasculature. Interestingly, increased
leptin concentration in the maternal circulation is reported
in GDM pregnancies [50, 51], a disease that also shows with
increased ROS generation [9, 11]. Thus, this adipocytokine
may also play a role in insulin resistance particularly in
diseases of pregnancy where ROS generation is increased.
4. Insulin Resistance in Pregnancy Diseases
4.1. Preeclampsia. Preeclampsia (PE) is a heterogeneous
pregnancy-speciﬁc multisystemic syndrome, deﬁned by the
occurrence of new onset hypertension (≥140/90mmHg)
and proteinuria (≥300mg/24 hours) after 20 weeks of ges-
tation [10, 52]. PE is of early onset (EOPE, <34 weeks of
gestation) or late onset (LOPE, ≥34 weeks of gestation)
[10, 53, 54]. EOPE and LOPE pregnancies associate with
impaired insulin response of the maternal [55] and foeto-
placental vasculature [20, 56]. However, not a clear mech-
anism explaining these alterations in EOPE and LOPE is
yet available.
Preferential activation of p42/44mapk and Akt is described
in the foetoplacental vasculature from PE. Preterm PE
(<37wg) with HELLP (Hemolysis, Elevated Liver enzymes,
and Low Platelet count) courses with increased phosphory-
lated p42/44mapk activation in villous trophoblast [57]. In
addition, the maternal plasma level from women with EOPE
shows a higher level of endothelin-1 (ET-1) [58], but reduced
Akt activity in the placenta [59] (Figure 3). Thus, an ET-1-
dependent inhibition of Akt reducing insulin signalling is
likely in this disease. Furthermore, since Akt activity posi-
tively correlates with NO generation in human foetal endo-
thelial cells [60], EOPE-associated foetoplacental vascular
dysfunction due to reduced NOS activity may involve
p44/42mapk/ET-1/Akt signalling. On the other hand, LOPE
pregnancies show with unaltered p42/44mapk [57] and unal-
tered [57] or decreased [61] Akt activity in the placenta.
Intriguingly, eNOS protein abundance and activator phos-
phorylation (Ser1177) are higher in HUVECs from LOPE
pregnancies [20], ﬁndings complemented by elevated
nitrate/nitrite ratio in human umbilical vein serum [62, 63],
but contrary to the reported lower nitrate/nitrite ratio [64]
and NOS-generation of L-citrulline from L-arginine (index
of NOS activity) [20] in this cell type. One plausible explana-
tion for reduced NOS activity in HUVECs from LOPE preg-
nancies is a predominant functional eﬀect of an increase of
eNOS inhibitor (Thr495) compared with the eﬀect of an acti-
vator (Ser1177) phosphorylation of this enzyme [20]. Earlier
studies show increased IRS-1 (Ser312) and IRS-2 (Ser731)
inhibitor phosphorylation in response to insulin in the pla-
centa from LOPE pregnancies [65]. Since IRS1/2 are key acti-
vators of Akt, LOPE-reduced Akt and NOS activity could
involve IRS1/2 inhibition. Thus, LOPE-associated impaired
insulin response could result from reduced IRS1/2/Akt/
eNOS signalling in the human foetoplacental vasculature.
Since activation of mTOR results in reduced IRS1/2 activity,
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it is likely that this signalling molecule is involved in the eﬀect
of EOPE and LOPE on NOS activity. However, there is no
information regarding the potential role of mTOR in the
aetiology of EOPE or LOPE in this vascular bed.
Several reports support the involvement of circulating
factors in the aetiology of PE including increased soluble
Fms-like tyrosine kinase 1 (sFlt1), soluble endoglin (sEng),
and reduced vascular endothelial growth factor (VEGF)
plasma levels [66, 67]. The increased plasma levels of ET-1
and sEng result in a higher sFlt1 plasma level [68]. The latter
reduces the availability of free VEGF-A to bind VEGF plasma
membrane receptors and inhibition of PI3K/Akt signalling,
Insulin
Insulin resistance
PGMO
PE
GDM IR‒A/SHcA IR‒B/IRSs
Akt
Reduced vasodilation
Adverse foetal outcome 
Risk of adulthood diseases
mTOR signalling
?
?
NO synthesis
Associated signalling mechanisms
−IRS1
−IRS1/2, +IR−A
−PDK1
−AMPK, +JNK
−AMPK, +S6K1, +TNF훼
−eNOS
−?
+eNOS
−PI3K (EOPE)
+(LOPE) −(EOPE) eNOS
−IRS1/2?
?
Disease of pregnancy
PGMO
PE
GDM
PGMO
PE
GDM
PGMO
PE
GDM
Figure 3: Potential involvement of Akt/mTOR in insulin resistance in the human foetoplacental unit from diseases of pregnancy.
Pregestational maternal obesity (PGMO), gestational diabetes mellitus (GDM), and preeclampsia are diseases of pregnancy where the
human foetoplacental endothelial function is reduced. The response of the placenta to insulin results from activation of insulin receptor A
(IR-A) via preferential signalling through Src homology 2 domain-containing transforming protein 1 type A (IR-A/SHcA) and insulin
receptor B (IR-B) via preferential signalling through insulin receptor substrates (IR-B/IRSs). The eﬀect of PGMO (represented as orange
bars), GDM (represented as green bars), and PE (represented as blue bars) in the cell signalling triggered by insulin causes an increase (+)
or a decrease (−) in the expression and activity of the indicated associated signalling molecules for each pathology. The defective action of
insulin is also documented for a reduced (⇩) activity of protein kinase B/Akt (Akt) due to signalling molecules that are reported for
PGMO and early onset PE (EOPE), a phenomenon that is less clear (?) in GDM pregnancies. Reduced Akt activity results in reduced
expression and activity of the mammalian target of rapamycin (mTOR) and its signalling in cells from PGMO, with a not clear
mechanism (?) in GDM and PE. These changes result in reduced activation of the endothelial nitric oxide (NO) synthase (eNOS) activity
leading to lower NO generation in PGMO and EOPE but increased eNOS activity in GDM and late onset PE (LOPE). These mechanisms
lead to a reduced Akt/mTOR signalling cascade in response to insulin (insulin resistance) in the foetoplacental vasculature. This
condition’s outcome is a reduced vasodilation with several other adverse foetal outcomes and higher risk of developing adulthood diseases.
PI3K: phosphatidylinositol 3 kinase; AMPK: adenosine monophosphate kinase; SK61: p70 S6 kinase 1; TNFα: tumour necrosis factor α;
PDK1: human 3-phosphoinositide-dependent protein kinase 1; JNK: c-Jun N-terminal kinases. Speciﬁc signalling mechanisms for each
molecule shown are described in the text. The magnitude of the bars represents the degree of involvement of the diseases of pregnancy at
the corresponding mechanism.
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including eNOS activity, in HUVECs [61, 69]. However,
inhibition of the PI3K/Akt signalling does not alter sEng
release from placenta explants or primary trophoblast in PE
[59]; therefore, a diﬀerential response to PI3K/Akt-mediated
insulin signalling in human foetoplacental endothelium ver-
sus trophoblast is likely. Interestingly, PI3K p85 phosphory-
lation at Tyr688 results in increased PI3K activity and Akt
signalling in placental tissue from EOPE pregnancies [70].
The latter was proposed as a compensatory mechanism to
the VEGF-reduced activation of PI3K/Akt signalling in this
disease. However, PI3K p85 activator phosphorylation is
unaltered in placentas from LOPE pregnancies [71], suggest-
ing a diﬀerent adaptive mechanism for insulin signalling in
EOPE and LOPE pregnancies.
4.2. Gestational Diabetes Mellitus. GDM refers to any degree
of glucose intolerance ﬁrst recognized during pregnancy,
diagnosed at 24–28 weeks of gestation [2]. GDM associates
with maternal obesity [72] and high risk of the mother to
develop T2DM [73]. GDM presents with clinical manifesta-
tions in the mother [74], foetus [75, 76], and newborn [75,
77], including hyperglycaemia and hyperinsulinemia (see
also [78, 79]). It is reported that IR-A expression and insulin
receptor β-subunit (β-IR) activity are increased in HUVECs
from GDM [80] (Figure 3). Interestingly, the ratio for p44/
42mapk/Akt is >1 due to increased p44/44mapk, but unaltered
Akt activity, suggesting preferential activation of IR-A in this
cell type. However, reduced IR-A, but increased IR-B expres-
sion, with a p44/42mapk/Akt ratio< 1 was reported in human
placental microvascular endothelium. Insulin restored IR-A
and IR-B expression and p44/42mapk/Akt ratio suggesting
diﬀerential activation of insulin signalling cascades due
to diﬀerential activation of IR subtypes in the macrovas-
cular and microvascular foetoplacental endothelium from
GDM pregnancies.
GDM associates with reduced uptake of the endogenous
nucleoside adenosine, a potent vasodilator in most tissues,
including the foetoplacental vasculature [4]. This phenome-
non results in elevated extracellular concentration of
adenosine enough to activate adenosine receptors [81],
preferentially A2A adenosine receptors (A2AAR), in the foe-
toplacental endothelium from GDM pregnancies [4, 11].
Interestingly, GDM also increases hCAT-1-mediated L-
arginine transport in HUVECs [82], which seems to link
with an increased eNOS activity and NO synthesis in this
cell type. The latter study also shows that insulin reversed
the GDM-increased L-arginine transport requiring A1AR
activation. Thus, diﬀerent adenosine receptors are involved
in the modulation of L-arginine transport in HUVECs from
normal compared with GDM pregnancies.
AMPK activation is lower in the placenta from women
with GDM [83, 84]. This ﬁnding is complemented by high
levels of TNF-α and activation of NF-κB, conditions leading
to increased synthesis of mediators of inﬂammation and
impaired insulin action [85, 86]. Thus, reduced AMPK
expression could associate with a proinﬂammatory state
and insulin resistance in GDM pregnancies. Since AMPK
inhibits mTOR activity [27, 44], a reduced AMPK activation
could result in increased mTOR activity in GDM. GDM also
courses with hyperleptinemia in the placenta [87, 88] and
reduced adiponectin level [89] in umbilical vein plasma.
However, precise mechanisms at insulin signalling in this
disease are unclear.
Insulin treatment of women with GDM (i.e., patients
under insulin therapy) reverses the GDM-associated mater-
nal and foetal hyperglycaemia and the increase in IRS-1
and PI3K p85α activity caused by this disease to values in
normal pregnancies [90]. However, the elevated level of lep-
tin in the foetal plasma and TNF-α and IL-1β levels in the
placenta from GDM pregnancies were unaltered by insulin
therapy. Thus, insulin therapy results in normalization of
foetal and maternal glycaemia but does not restore the
impaired insulin signalling in foetoplacental endothelium in
this disease. Indeed, we recently reported that insulin therapy
in women with GDM did not restore the increased L-
arginine uptake and NO synthesis seen in HUVECs from
women with GDM under a controlled diet [91]. It is worrying
that a higher chance to be born large for gestational age is
reported as an outcome for insulin therapy [92] or in preg-
nant women treated with insulin and metformin [93] and
in a larger number (~25%) of infants showing one or more
episodes with neonatal morbidity where neonatal asymptom-
atic hypoglycaemia was the most frequent [94]. We empha-
size our call regarding the still unclear eﬀect of maternal
insulin therapy on foetus development, the newborn, and
postnatal life [2, 4, 9, 91, 95].
4.3. Pregestational Maternal Obesity. The World Health
Organization deﬁnes obesity as individuals with a body mass
index (BMI)> 30 kg/m2, a disease that has reached epidemic
characteristics worldwide [1]. One of the main risks of an
abnormal nutritional state is its association with metabolic
syndrome, a condition with high multiple risk factors for
chronic diseases, including diabetes mellitus, cardiovascular
diseases, stroke, hypertension, and cancer [96].
Few studies address cell signalling in PGMO. Epidemio-
logical evidence shows that children born to PGMO pregnan-
cies show hyperinsulinemia and elevated insulin resistance
[97, 98]. Additionally, infants and adolescents from PGMO
pregnancies exhibit high risk of developing obesity [99, 100]
and associate with higher cardiovascular risk in adulthood
[100]. Interestingly, umbilical cords from PGMO pregnan-
cies show a gene proﬁle related with reduced insulin sensi-
tivity [101], including downregulation of PDPK1 (coding
for PDK1) involved in D-glucose uptake and storage
[101]. However, direct functional evidence for insulin eﬀect
on foetoplacental endothelium in PGMO is limited
(Table 1).
PGMO pregnancies associate with reduced activity of
AMPK [102] but increased activity of mTOR [103] in the
placenta. These ﬁndings correlate with reduced maternal
plasma adiponectin levels [104]. Since JNK activation is also
increased in human placentas from PGMO pregnancies
[105], a potential insulin resistance condition resulting from
IRS inhibition may involve adiponectin-reduced level-
dependent AMPK inactivation, increased mTOR activity,
and reduced Akt signalling, in this abnormal condition of
pregnancy (Figure 3).
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Table 1: Eﬀect of pathologies of pregnancy on insulin signalling in the human foetoplacental vasculature.
Cell or tissue Molecule or activity
Eﬀect of the
pathology
Eﬀect of
insulin
References
Preeclampsia
Placenta (EOPE) p44/42mapk Increase na [57]
Placenta (EOPE) ET-1, ETA, and ETB (mRNA) Increase na [108]
Placenta Akt-Ser473 Decrease na [61]
Placenta eNOS Increase na [109]
Placenta (LOPE)
β-IR, IRS-1-Tyr465, IRS-1-Ser312,
and IRS-2-Ser731
No eﬀect Increase [65]
Placenta (LOPE) Akt-Ser473 No eﬀect Increase [110]
HUVECs (LOPE) eNOS-Thr495, eNOS-Ser1177 Increase Restored [20]
HUVECs (LOPE) eNOS-Ser1177 Increase na [111]
HUVECs (EOPE) eNOS Decrease na [111]
HUVECs eNOS Decrease na [112]
HUVECs (LOPE) L-Arginine transport Increase Restored [20]
HUVECs (LOPE)∗ hCAT-1 Increase Increase [20]
Gestational diabetes mellitus
Placenta IRs Increase na [113]
Placenta (insulin therapy)∗∗ β-IR Increase Restored [90]
Placenta IRS-1 Increase na [113]
Placenta (insulin therapy) IRS-1 Increase Restored [90]
Placenta (insulin therapy) IRS-2 Increase Increase [90]
Placenta PI3K p85α Increase Restored [90]
Placenta PI3K p85α Increase na [113]
Placenta (insulin therapy) PI3K p110 Increase No eﬀect [90]
Placenta∗∗∗ mTOR-Ser2448, S6K1-Thr421/Ser424 Increase na [83]
Placenta∗∗∗∗ S6K1-Thr389, 4EBP1-Thr37/46 Increase na [114]
Placenta∗∗∗ 4EBP1-Thr37/46 Increase na [83]
Placenta AMPK (mRNA) Decrease na [88]
Placenta Adiponectin Decrease na [115]
Placenta TNF-α Increase na [85, 116]
Placenta (insulin therapy) TNF-α Unaltered na [86]
Placenta IL-1β Increase na [116]
Placenta Leptin receptor Increase na [88]
Trophoblast Leptin receptor Increase na [87]
HUVECs IR-A (mRNA) Increase Restored [21]
HUVECs Akt-Ser473 No eﬀect Increase [80]
HUVECs eNOS, eNOS-Ser1177 Increase Restored [80]
HUVECs p44/42mapk-Thr202/204 Increase Restored [80]
HUVECs (insulin therapy) eNOS, eNOS-Ser1177 Increase Restored [117]
HUVECs hENT1, adenosine transport Decrease Increase [21, 80]
HUVECs L-Arginine transport Increase Restored [82]
HUVECs (insulin therapy) L-Arginine transport Increase Restored [117]
hPMECs p44/42mapk-Thr202/204, Akt-Ser473 Decrease Restored [118]
hPMECs IR-A (mRNA) Decrease Restored [118]
hPMECs IR-B (mRNA) Increase Restored [118]
hPMECs hENT1 Decrease No eﬀect [118]
hPMECs hENT2 Decrease Restored [118]
hPMECs hENT1 transport activity Decrease No eﬀect [118]
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5. Concluding Comments
Insulin regulates canonical signal transduction pathways ini-
tiated by activation of IR-A/p44/42mapk and IR-B/Akt in
human foetoplacental vasculature in healthy pregnancies
(Figure 3). IRS-1 and IRS-2 are upstream activators of the
PI3K/Akt signalling pathway leading to activation of mTOR.
SHcA 42 and SHcA 56 activate p44/42mapk leading to
increased release of vasoconstrictors, such as ET-1. Insulin
resistance associated with PGMO, PE, and GDM results in
foetoplacental vascular dysfunction and altered vascular
reactivity to insulin. A likely potential common point in insu-
lin resistance in these diseases is a reduced Akt signalling
resulting in lower activation of mTOR and eNOS. A role
for AMPK in this phenomenon is not clear, but the involve-
ment of this molecule is likely since its activation positively
correlates with mTOR activity. A role of NO in the response
to insulin in the foetoplacental endothelium in diseases of
pregnancy is well described [4, 10, 12]. Thus, modulation of
NO generation could be a ﬁnal target of an abnormal IR-A/
SHcA/p44/42mapk- and IR-B/IRSs/Akt-mediated signalling
via Akt/mTOR in insulin resistance at the human foetopla-
cental vasculature. A therapy targeting these signalling mole-
cules could be beneﬁcial to improve insulin response in these
diseases. PGMO is a risk factor for developing PE [106, 107]
and GDM [107]. Thus, characterizing potential common sig-
nalling mechanisms for PGMO, PE, and GDM will facilitate
the design of an approach to prevent insulin resistance in the
co-occurrence of these or other disorders in pregnancy, thus
reducing or abolishing their deleterious consequences for the
mother, the foetus, and the newborn.
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Table 1: Continued.
Cell or tissue Molecule or activity
Eﬀect of the
pathology
Eﬀect of
insulin
References
hPMECs hENT2 transport activity Decrease Restored [118]
Umbilical cord plasma Leptin Increase na [88]
Umbilical cord plasma Adiponectin Decrease na [89]
Pregestational maternal obesity
Placenta AMPK-Thr172 Decrease na [102, 103]
Placenta AMPK Decrease na [103]
Placenta S6K1-Thr389 Increase na [88, 119]
Placenta JNK-Thr183/Tyr185 Increase na [119]
Placenta mTOR (mRNA) Decrease na [102, 103]
Placenta IRS-1 (mRNA) Decrease na [103]
AMPK: adenosine monophosphate protein kinase; AMPK-Thr172: AMPK phosphorylated at threonine 172; S6K1: S6 kinase 1; S6K1-Thr421/Ser424: S6K1
phosphorylated at threonine 421 and serine 424; S6K1-Thr389: S6K1 phosphorylated at threonine 389; JNK: c-Jun N-terminal kinases; JNK-Thr183/Tyr185:
JNK phosphorylated at threonine 183 and tyrosine 185; mTOR: mammalian target of rapamycin; IRS-1: insulin receptor substrate 1; IRS-1-Tyr465: IRS-1
phosphorylated at tyrosine 465; IRS-1-Ser312: IRS-1 phosphorylated at serine 312; IRS-2: insulin receptor substrate 2; IRS-2-Ser731: IRS-2 phosphorylated at
serine 731; EOPE: early-onset preeclampsia; LOPE: late-onset preeclampsia; p44/42mapk: 44 and 42 kDa mitogen-activated protein kinases; p44/42mapk-
Thr202/204: p44mapk phosphorylated at threonine 202 and p42mapk phosphorylated at threonine 204; Akt: protein kinase B/Akt; Akt-Ser473: Akt
phosphorylated at serine 473; eNOS: endothelial nitric oxide synthase; eNOS-Thr495: eNOS phosphorylated at threonine 495; eNOS-Ser1177: eNOS
phosphorylated at serine 1177; IRs: insulin receptors; IR-A: insulin receptor A; IR-B: insulin receptor B; β-IR: insulin receptor β-subunit; PI3K:
phosphatidylinositol 3 kinase; PI3K p85α: p85α regulatory subunit of PI3K; PI3K p110: p110 catalytic subunit of PI3K; EGFR: epidermal growth factor
receptor; mTOR-Ser2448: mTOR phosphorylated at serine 2448; S6K1-Tyr389: S6K1 phosphorylated at threonine 389; 4EBP1: eukaryotic translation
initiation factor 4E binding protein 1; 4EBP1-Thr37/46: 4EBP1 phosphorylated at threonine 37 and 46; TNF-α: tumour necrosis factor α; AP1: activator
protein 1; NF-κB: nuclear factor-kappa B; ET-1: endothelin 1; ETA: endothelin receptor type A; ETB: endothelin receptor type B; IL-1β: interleukin 1β;
hCAT-1: human cationic amino acid transporter 1; hENT1: human equilibrative nucleoside transporters 1; hENT2: human equilibrative nucleoside
transporters 2; HUVECs: human umbilical vein endothelial cells; hPMECs: human placental microvascular endothelial cells. ∗Cells incubated with
insulin in the presence of ZM-241385 (A2AAR antagonist).
∗∗GDM mothers were obese. ∗∗∗Results include GDM mother under diet and insulin
therapy. ∗∗∗∗GDM mother on oral insulin-sensitizing antidiabetic undeﬁned medication. na: not assayed.
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